Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis
OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective,...
Gespeichert in:
Veröffentlicht in: | Critical care medicine 2002-05, Vol.30 (5), p.974-980 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 980 |
---|---|
container_issue | 5 |
container_start_page | 974 |
container_title | Critical care medicine |
container_volume | 30 |
creator | Goldfarb, Roy D Marton, Anita Szabó, Éva Virág, László Salzman, Andrew L Glock, Dana Akhter, Imran McCarthy, Robert Parrillo, Joseph E Szabó, Csaba |
description | OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.
DESIGNProspective, random animal study.
SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center.
SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples.
INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.
MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p < .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.
CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis. |
doi_str_mv | 10.1097/00003246-200205000-00004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71677540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71677540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</originalsourceid><addsrcrecordid>eNp1ksGOFCEQhonRuLOrr2C4aDSxlW6g6T5uNrqabKIHPROaLtIo07QUM5u5-Qw-io_kk0g7o3uSC1Tx_X8l_BBCa_aqZr16zcrijWirhrGGyVJVa0vcI5ta8lI0Pb9PNoz1rOKi52fkHPELY7WQij8kZ3XRtapnG_LjY4oZbPZ7oOBcOdHoqKFz3EN4SZdyOWfq58kPPse0Xi4xHJ6bEeaIfgYqf33_WY1-mSIuk8lQJT9EhBcUD3OeIBuEoi-WS0x2FWzjCGE1QthDAjoYmyF5E0pjQY-PyANnAsLj035BPr998-nqXXXz4fr91eVNZYVsRMUVsEFwJ7qO81FyLjtVt8Yx0akG7NjaVpq2HXpViNIEV2RMGG5d0won-AV5dvRdUvy2A8x669FCCGaGuENd3JSSghWwO4I2RcQETi_Jb0066JrpNQ_9Nw_9L48_rXXGk9OM3bCF8U54CqAAT0-AQWuCS2a2Hu84USsmeVc4ceRuYyivhV_D7haSnsCEPOn__Qf-G4japAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71677540</pqid></control><display><type>article</type><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</creator><creatorcontrib>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</creatorcontrib><description>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.
DESIGNProspective, random animal study.
SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center.
SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples.
INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.
MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p < .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.
CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-200205000-00004</identifier><identifier>PMID: 12006790</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Bacterial Infections - drug therapy ; Biological and medical sciences ; Disease Models, Animal ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Emergency and intensive care: infection, septic shock ; Enzyme Inhibitors - therapeutic use ; Escherichia coli Infections - drug therapy ; Hemodynamics - drug effects ; Intensive care medicine ; Medical sciences ; Peritonitis - drug therapy ; Phenanthrenes - therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors ; Prospective Studies ; Random Allocation ; Swine ; Tumor Necrosis Factor-alpha - analysis</subject><ispartof>Critical care medicine, 2002-05, Vol.30 (5), p.974-980</ispartof><rights>2002 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</citedby><cites>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14170538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12006790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldfarb, Roy D</creatorcontrib><creatorcontrib>Marton, Anita</creatorcontrib><creatorcontrib>Szabó, Éva</creatorcontrib><creatorcontrib>Virág, László</creatorcontrib><creatorcontrib>Salzman, Andrew L</creatorcontrib><creatorcontrib>Glock, Dana</creatorcontrib><creatorcontrib>Akhter, Imran</creatorcontrib><creatorcontrib>McCarthy, Robert</creatorcontrib><creatorcontrib>Parrillo, Joseph E</creatorcontrib><creatorcontrib>Szabó, Csaba</creatorcontrib><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.
DESIGNProspective, random animal study.
SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center.
SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples.
INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.
MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p < .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.
CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Bacterial Infections - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Hemodynamics - drug effects</subject><subject>Intensive care medicine</subject><subject>Medical sciences</subject><subject>Peritonitis - drug therapy</subject><subject>Phenanthrenes - therapeutic use</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Swine</subject><subject>Tumor Necrosis Factor-alpha - analysis</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ksGOFCEQhonRuLOrr2C4aDSxlW6g6T5uNrqabKIHPROaLtIo07QUM5u5-Qw-io_kk0g7o3uSC1Tx_X8l_BBCa_aqZr16zcrijWirhrGGyVJVa0vcI5ta8lI0Pb9PNoz1rOKi52fkHPELY7WQij8kZ3XRtapnG_LjY4oZbPZ7oOBcOdHoqKFz3EN4SZdyOWfq58kPPse0Xi4xHJ6bEeaIfgYqf33_WY1-mSIuk8lQJT9EhBcUD3OeIBuEoi-WS0x2FWzjCGE1QthDAjoYmyF5E0pjQY-PyANnAsLj035BPr998-nqXXXz4fr91eVNZYVsRMUVsEFwJ7qO81FyLjtVt8Yx0akG7NjaVpq2HXpViNIEV2RMGG5d0won-AV5dvRdUvy2A8x669FCCGaGuENd3JSSghWwO4I2RcQETi_Jb0066JrpNQ_9Nw_9L48_rXXGk9OM3bCF8U54CqAAT0-AQWuCS2a2Hu84USsmeVc4ceRuYyivhV_D7haSnsCEPOn__Qf-G4japAA</recordid><startdate>200205</startdate><enddate>200205</enddate><creator>Goldfarb, Roy D</creator><creator>Marton, Anita</creator><creator>Szabó, Éva</creator><creator>Virág, László</creator><creator>Salzman, Andrew L</creator><creator>Glock, Dana</creator><creator>Akhter, Imran</creator><creator>McCarthy, Robert</creator><creator>Parrillo, Joseph E</creator><creator>Szabó, Csaba</creator><general>by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200205</creationdate><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><author>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Bacterial Infections - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Hemodynamics - drug effects</topic><topic>Intensive care medicine</topic><topic>Medical sciences</topic><topic>Peritonitis - drug therapy</topic><topic>Phenanthrenes - therapeutic use</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Swine</topic><topic>Tumor Necrosis Factor-alpha - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldfarb, Roy D</creatorcontrib><creatorcontrib>Marton, Anita</creatorcontrib><creatorcontrib>Szabó, Éva</creatorcontrib><creatorcontrib>Virág, László</creatorcontrib><creatorcontrib>Salzman, Andrew L</creatorcontrib><creatorcontrib>Glock, Dana</creatorcontrib><creatorcontrib>Akhter, Imran</creatorcontrib><creatorcontrib>McCarthy, Robert</creatorcontrib><creatorcontrib>Parrillo, Joseph E</creatorcontrib><creatorcontrib>Szabó, Csaba</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldfarb, Roy D</au><au>Marton, Anita</au><au>Szabó, Éva</au><au>Virág, László</au><au>Salzman, Andrew L</au><au>Glock, Dana</au><au>Akhter, Imran</au><au>McCarthy, Robert</au><au>Parrillo, Joseph E</au><au>Szabó, Csaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2002-05</date><risdate>2002</risdate><volume>30</volume><issue>5</issue><spage>974</spage><epage>980</epage><pages>974-980</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.
DESIGNProspective, random animal study.
SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center.
SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples.
INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.
MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p < .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.
CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</abstract><cop>Hagerstown, MD</cop><pub>by the Society of Critical Care Medicine and Lippincott Williams & Wilkins</pub><pmid>12006790</pmid><doi>10.1097/00003246-200205000-00004</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-3493 |
ispartof | Critical care medicine, 2002-05, Vol.30 (5), p.974-980 |
issn | 0090-3493 1530-0293 |
language | eng |
recordid | cdi_proquest_miscellaneous_71677540 |
source | Journals@Ovid Ovid Autoload; MEDLINE |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Bacterial Infections - drug therapy Biological and medical sciences Disease Models, Animal Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care Emergency and intensive care: infection, septic shock Enzyme Inhibitors - therapeutic use Escherichia coli Infections - drug therapy Hemodynamics - drug effects Intensive care medicine Medical sciences Peritonitis - drug therapy Phenanthrenes - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors Prospective Studies Random Allocation Swine Tumor Necrosis Factor-alpha - analysis |
title | Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20a%20novel,%20potent%20inhibitor%20of%20poly(adenosine%205%E2%80%B2-diphosphate-ribose)%20synthetase%20in%20a%20porcine%20model%20of%20severe%20bacterial%20sepsis&rft.jtitle=Critical%20care%20medicine&rft.au=Goldfarb,%20Roy%20D&rft.date=2002-05&rft.volume=30&rft.issue=5&rft.spage=974&rft.epage=980&rft.pages=974-980&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/00003246-200205000-00004&rft_dat=%3Cproquest_cross%3E71677540%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71677540&rft_id=info:pmid/12006790&rfr_iscdi=true |